Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Class A serine β-lactamase is a bacterial enzyme that represents the most widespread antibiotic resistance mechanism against β-lactam drugs, including penicillins and cephalosporins.[2] These enzymes function as serine-dependent hydrolases that catalyze the breakdown of β-lactam antibiotics through formation of an acyl-enzyme intermediate, utilizing conserved amino acid residues including Ser70 (catalytic residue), Glu166, and Asn170 located on the characteristic omega (Ω) loop structure.[1][3][4] Class A β-lactamases evolved from penicillin-binding proteins (PBPs) through the formation of the Ω-loop, which enables more efficient deacylation and inactivation of antibiotics compared to the original transpeptidase targets.[1] Common variants include TEM-1 (the most frequently encountered), CTX-M enzymes (extended-spectrum variants), and KPC enzymes (carbapenem-hydrolyzing variants).[3][4] As a therapeutic target, inhibiting Class A β-lactamases is critical for restoring the efficacy of β-lactam antibiotics against resistant bacterial pathogens; current approaches include mechanism-based inhibitors like clavulanate and emerging boronic acid-based non-β-lactam inhibitors designed through structure-based drug design.[2]
Serine-dependent hydrolysis of β-lactam antibiotics through acyl-enzyme intermediate formation[6] Active site catalysis utilizing conserved Ser70 residue[3] Deacylation via Glu166 and Asn170 residues located on the omega (Ω) loop[1][4] Faster hydrolysis and inactivation of β-lactams compared to inhibition by penicillin-binding proteins (PBPs)[1] Formation of tetrahedral geometry at boron atoms in boronic acid complexes for inhibitor binding[2]
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Class A serine β-lactamase (Class A β-lactamase).